AccelBio’s Heart-Kidney Organ Screen is an advanced Preclinical Human Organoid-based Drug Screening Service designed to accelerate lead identification and safety validation for research institutions and pharmaceutical and biotechnology companies. Developed from human induced pluripotent stem cells (hiPSCs), our organoids faithfully reproduce the cellular diversity, structural complexity, and functional characteristics of native human organs—offering a level of physiological relevance far beyond traditional 2D cultures or animal models. At the core of our technology lies a dual-organ focus on the heart and kidney—two critical organs often implicated in drug-induced toxicity. Our proprietary methodology enables the generation of organoids with advanced tissue architecture and functionality, providing robust and reproducible data that meet the demands of modern preclinical assessment. The platform is high-throughput compatible, allowing scalable screening of large compound libraries under physiologically relevant conditions. Leveraging the adaptability of hiPSC-derived models, organoids can be customized to mimic specific disease phenotypes or genetic backgrounds, enabling precise evaluation of efficacy and toxicity in personalized contexts. Moreover, their developmental flexibility allows modeling of distinct maturation stages—from early organogenesis to adult-like tissues—supporting studies of both congenital and adult-onset diseases. By combining human relevance, scalability, and disease specificity, our service empowers researchers to identify safer, more effective therapeutics with unprecedented translational accuracy.